Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06489249 · ClinicalTrials.gov registry record · Early Phase 1

Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use

A Early Phase 1 study of Inflammation and Endothelial Dysfunction, sponsored by University of Iowa.

Recruiting
Registry status
Early Phase 1
Development phase
24
Enrollment target
2
Study locations

NCT06489249: Recruiting Early Phase 1 study of Inflammation and Endothelial Dysfunction, sponsored by University of Iowa.

NCT06489249 is a Early Phase 1 study of Inflammation and Endothelial Dysfunction that is actively recruiting participants, run by University of Iowa. The registered enrollment target is 24 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06489249, a Early Phase 1 study of Inflammation and Endothelial Dysfunction, is actively recruiting participants, sponsored by University of Iowa.

RECRUITING
Registry status
Early Phase 1
Development phase
24 participants
Enrollment target
2
Study locations

Study Summary

The use of electronic nicotine delivery systems, or e-cigarettes - colloquially referred to as "vaping" - in the United States has increased exponentially since their introduction to the US market in 2007. Prevalence of ever and current e-cigarette use is highest among teenagers and young adults with 16-28% of this population having reported vaping. While the majority of e-cigarette users are current tobacco smokers, 32.5% of current e-cigarette users are never- or former-smokers, representing a growing population of young adults who exclusively vape. While e-cigarettes have been marketed as a safer alternative to tobacco cigarettes, clinical studies examining these claims are limited. Cardiovascular disease (CVD) is the primary cause of premature death among tobacco cigarette smokers and reductions in vascular endothelial function, a significant predictor of future CVD, are detectible in otherwise healthy young adults who smoke. Despite the explosion in e-cigarette use among young adults, the health effects - especially the effects on mechanisms of vascular function - of these devices remain relatively unexplored. The purpose of this study is to directly asses the mechanistic role of inflammation in this dysfunction.

Primary Outcome

Endothelium-dependent vasodilation assessed as cutaneous conductance response (cutaneous conductance = local red blood cell flux/mean arterial pressure; %maximum) to local heating of the skin (42 degrees Celcius).

Interventions

  • DRUG Placebo
  • DRUG Salsalate 750 MG Oral Tablet [DISALCID]

Study Locations (2)

Iowa

  • Iowa Bioscience Innovation Facility - Iowa City
  • University of Iowa - Iowa City

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2024-08-15
Est. Completion 2026-10
Phase Early Phase 1
University of Iowa

228 total trials

What NCT06489249 shows while recruiting

NCT06489249 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (92% lower).

The record links to 3 conditions, with Inflammation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06489249 reports a single indexed study location in Iowa.

Frequently Asked Questions

What is clinical trial NCT06489249 about?

NCT06489249 is a clinical study titled "Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use". The use of electronic nicotine delivery systems, or e-cigarettes - colloquially referred to as "vaping" - in the United States has increased exponentially since their introduction to the US market in 2007. Prevalence of ever and current e-cigarette use is highest among teenagers and young adults wit...

What is the current status of trial NCT06489249?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2024-08-15. Estimated completion is 2026-10.

What conditions does trial NCT06489249 study?

This clinical trial studies the following conditions: Inflammation, Endothelial Dysfunction, Electronic Cigarette Use.

What interventions are being tested in trial NCT06489249?

The interventions under investigation include: Placebo (DRUG), Salsalate 750 MG Oral Tablet [DISALCID] (DRUG).

Who is sponsoring clinical trial NCT06489249?

This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06489249 being conducted?

This trial has 2 study locations across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Inflammation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06489249's enrollment target sits among peer trials

24 117th of 132 higher than 16 of 132 other Inflammation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Inflammation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06489249, the US trial registry maintained by the National Library of Medicine. NCT06489249 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.